



Haleon plc: Completion of acquisition of remaining 12% in China JV

27 June 2025: Haleon plc (the "Company" or "Haleon") today announces that it has completed the acquisition announced on 15 April 2025, of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical Co. Ltd ("TSKF"), its OTC joint venture in China for a total consideration of RMB 1,623 million (c. £0.2 billion). As a result, TSKF is now a wholly owned subsidiary of Haleon.

China is a key market for Haleon which is underpinned by favourable structural drivers. The acquisition of TSKF which has a long heritage of operational excellence will enable Haleon to drive category growth in one of the fastest growing OTC markets globally. TSKF accounted for c. 40% of Haleon's China revenues in 2024 and manufactures and/or distributes leading brands such as Fenbid, Voltaren and Bactroban. This acquisition will deliver increased strategic, and operational flexibility, and is fully consistent with our capital allocation priorities to drive attractive returns for shareholders and maintain a strong investment grade balance sheet.

Enquiries

Investors

Jo Russell +44 7787 392441
Rakesh Patel +44 7552 484646
Emma White +44 7823 523562
Email: investor-relations@haleon.com

Media

Zoë Bird +44 7736 746167
Victoria Durman +44 7894 505730
Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as *Advil*, *Centrum*, *Otrivin*, *Panadol*, *parodontax*, *Polident*, *Sensodyne*, *Theraflu* and *Voltaren* - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACQFRMPTMTMTMRA